Loading…
Kyntra Bio, Inc. is projected to rise to $8.22 by 2027, a +17% move from its current price of $7.01. KYNB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.85 | $7.01 | $7.18 | +0.07% |
| May 30 | $6.79 | $7.02 | $7.25 | +0.13% |
| May 31 | $6.75 | $7.02 | $7.31 | +0.20% |
| Jun 1 | $6.71 | $7.03 | $7.36 | +0.26% |
| Jun 2 | $6.67 | $7.03 | $7.41 | +0.33% |
| Jun 3 | $6.65 | $7.04 | $7.45 | +0.39% |
| Jun 4 | $6.62 | $7.04 | $7.49 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.62 | $7.04 | $7.49 | +0.46% |
| Week 2 | $6.48 | $7.07 | $7.72 | +0.92% |
| Week 3 | $6.39 | $7.11 | $7.91 | +1.38% |
| Week 4 | $6.31 | $7.14 | $8.08 | +1.84% |
| Week 5 | $6.25 | $7.17 | $8.23 | +2.30% |
| Week 6 | $6.19 | $7.20 | $8.38 | +2.77% |
| Week 7 | $6.15 | $7.24 | $8.52 | +3.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
The company was formerly known as FibroGen, Inc. and changed its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Kyntra Bio, Inc. (KYNB) is a healthcare company operating in the biopharmaceutical sector. The stock is currently priced at $6.99 per share, with a market cap of $28.3M, and it ranks 4832.
The near-term forecast shows a flat-to-modest path in 2026 (avg $6.99, ROI 0), followed by a bullish trajectory in the ensuing years, culminating in stronger long-term upside. For reference, 2040 is forecast at an avg of $17.52 with ROI 150.6%, and 2050 at an avg of $27.34 with ROI 291.2%.
A major floor 7.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (3.0% away) — a key level to hold.
The nearest ceiling, 4.7% above — a clean break opens room to run.
A major ceiling 30.4% above — clearing it would confirm fresh momentum.
Key KYNB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYNB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.95 | Buy | $6.94 | Buy |
| MA 10 | $6.92 | Buy | $6.95 | Buy |
| MA 20 | $7.01 | Buy | $6.98 | Buy |
| MA 50 | $7.03 | Sell | $7.13 | Sell |
| MA 100 | $7.53 | Sell | $7.54 | Sell |
| MA 200 | $8.92 | Sell | $8.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.09 | Neutral |
| Stoch RSI (14) | 73.94 | Neutral |
| CCI (20) | 2.82 | Neutral |
| Williams %R (14) | -50.59 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 0.86 | Buy |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 49.41 | Neutral |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | -0.12 | Sell |
| Ultimate (7,14,28) | 58.57 | Neutral |
| Momentum (10) | -0.21 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 6.96 | Buy |
| ADX (14) | 6.60 | Neutral |
| ATR (14) | 0.12 | Info |
The current sentiment is BEARISH, with RSI 14 at 50. The stock’s near-term moving averages are SMA50 at $7.03 and SMA200 at $8.93, providing nearby trend references. Support is at $6.80 and resistance at $7.37, framing a tight near-term range.
Over the last 30 days, the price has traded within a low of $5.99 and a high of $8.15, highlighting limited short-term volatility relative to the broader range. The stock also features an annualized volatility of 40%.
These near-term indicators reflect a cautious stance despite the longer-term forecast suggesting upside potential beyond 2026.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.46 | $7.01 | $9.49 | 0% | Neutral | |
| $6.61 | $8.22 | $10.77 | +17% | Neutral | |
| $6.33 | $8.05 | $10.88 | +15% | Neutral | |
| $6.48 | $8.41 | $11.65 | +20% | Neutral | |
| $6.58 | $8.68 | $12.29 | +24% | Bullish | |
| $6.69 | $8.95 | $12.91 | +28% | Bullish | |
| $7.86 | $10.68 | $15.66 | +52% | Bullish | |
| $8.57 | $11.79 | $17.55 | +68% | Bullish | |
| $8.70 | $12.13 | $18.30 | +73% | Bullish | |
| $8.50 | $12.00 | $18.34 | +71% | Bullish | |
| $11.84 | $17.65 | $28.50 | +152% | Bullish | |
| $16.79 | $27.45 | $48.04 | +292% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.46 | $7.01 | $8.23 | +0.00% |
| June 2026 | $6.22 | $7.28 | $8.71 | +3.88% |
| July 2026 | $6.31 | $7.44 | $9.00 | +2.15% |
| August 2026 | $6.24 | $7.40 | $9.03 | -0.56% |
| September 2026 | $6.34 | $7.55 | $9.29 | +2.08% |
| October 2026 | $6.52 | $7.80 | $9.66 | +3.33% |
| November 2026 | $6.44 | $7.74 | $9.63 | -0.82% |
| December 2026 | $6.29 | $7.58 | $9.49 | -2.02% |
Click any year to see its month-by-month KYNB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kyntra Bio, Inc.'s 2026 outlook centres on $7.01, within a $6.46 to $9.49 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, KYNB could reach as high as $10.77, with a base case around $8.22 and support toward $6.61 — roughly +17% from $7.01. Price action looks broadly range-bound.
Expect KYNB to range from $6.33 to $10.88 through 2028. The $8.05 average target implies a +15% move from current prices. That is -2% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The KYNB price prediction for 2029 points to an average of $8.41 (low $6.48, high $11.65) — a potential gain of +20% on today's $7.01. Price action looks broadly range-bound.
In 2030, KYNB is projected to trade between $6.58 and $12.29, averaging $8.68 — a potential gain of +24% from today's $7.01. That is up +3% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Kyntra Bio, Inc.'s 2031 outlook centres on $8.95, within a $6.69 to $12.91 range. That is up +3% on the projected 2030 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2032, KYNB could reach as high as $15.66, with a base case around $10.68 and support toward $7.86 — roughly +52% from $7.01. Buyers look set to stay in control over this stretch.
Expect KYNB to range from $8.57 to $17.55 through 2033. The $11.79 average target implies a +68% move from current prices. That is up +10% on the projected 2032 average. Momentum favours further upside here.
The KYNB price prediction for 2034 points to an average of $12.13 (low $8.70, high $18.30) — a potential gain of +73% on today's $7.01. Buyers look set to stay in control over this stretch.
In 2035, KYNB is projected to trade between $8.50 and $18.34, averaging $12.00 — a potential gain of +71% from today's $7.01. That is -1% versus the projected 2034 average. Momentum favours further upside here.
Kyntra Bio, Inc.'s 2040 outlook centres on $17.65, within a $11.84 to $28.50 range. That is up +47% on the projected 2035 average. That marks a +152% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, KYNB could reach as high as $48.04, with a base case around $27.45 and support toward $16.79 — roughly +292% from $7.01. Momentum favours further upside here.
Investing $1,000 in KYNB today (≈ 142.653352 KYNB) could be worth
$3,915.64
+$2,915.64 (+292%) by 2050 · US Dollar
Based on the average projected KYNB price of $27.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYNBwould be worth at today's price.
$1,000 invested in KYNB on May 27, 2025 (≈ 124.2236 KYNB) would be worth
$870.81
-$129.19 (-12.9%) today · 0.87× · US Dollar
Based on a KYNB entry price of $8.05 vs. today's $7.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.95 | $1,008.63 | +0.9% |
| 1 month ago | $7.03 | $997.16 | -0.3% |
| 3 months ago | $6.97 | $1,005.74 | +0.6% |
| 6 months ago | $8.8 | $796.59 | -20.3% |
| 1 year ago | $8.05 | $870.81 | -12.9% |
| All time (5.0y) ago | $545.75 | $12.84 | -98.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYNB forecast.
Our base-case forecast reaches $14.00 around 2040.
Implied market cap at $14.00: $56.67M
The multi-year forecast shows a path of gradual-to-strong appreciation from the late 2020s into the 2030s and beyond. In 2027 the avg price is forecast at $8.22 with ROI 17.6% and bullish sentiment; 2028 shows an avg of $8.00 with ROI 14.5% and neutral sentiment; 2029 at $8.39 avg with ROI 20% and bullish sentiment. The 2030 forecast shows an avg of $8.68 with ROI 24.2% and bullish sentiment, and 2031 at $8.88 avg with ROI 27%.
In 2032 the avg rises to $10.68 (ROI 52.8%), 2033 to $11.81 (ROI 68.9%), 2034 to $12.00 (ROI 71.6%), and 2035 to $11.96 (ROI 71.1%), all characterized as bullish. The long-range view strengthens significantly by 2040 with an avg of $17.52 and ROI 150.6%, and by 2050 an avg of $27.34 with ROI 291.2%, both bullish.
These figures are estimates, not guarantees, and actual results may vary. The forecast implies meaningful upside potential over the coming years but remains subject to market and clinical development risks, including variability in program progress and collaboration dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows min $6.58, avg $8.68, max $12.29 with ROI 24.2% and bullish sentiment.
Long-term forecasts show bullish sentiment from 2027 onward, with 2040 avg $17.52 (ROI 150.6%) and 2050 avg $27.34 (ROI 291.2%). The 2026 avg is $6.99 (ROI 0) and the near term is mixed with bearish sentiment noted.
Yes. The forecasted max values include $10.78 in 2027 and $10.82 in 2028, with higher maxes in later years up to $12.29 in 2030.
Current price is $6.99 and market cap is $28.3M.
RSI14 is 50; SMA50 is $7.03; SMA200 is $8.93; support is $6.80; resistance is $7.37; 30-day range is $5.99 to $8.15; annualized volatility is 40%.
Kyntra Bio, Inc. Community Discussion
0Share your Kyntra Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.